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Summary  
A total of 119 patients were included in a randomized, double-blind, placebo-controlled trial in order to assess the 
S/DMOAD properties in OA of chondroitin sulfate (CS 4&6, 3 x 400 mg/day, Condrosulf '~IBSA, Lugano, CH). 
Posteranterior roentgenographies of the interphalangeal (IP) joints were carried out at the start of the study and 
at yearly intervals. This enabled the investigators to document the radiological progression of the anatomical lesions 
in the pathological finger joints over a 3-year period. It was shown that the progression of OA in the IP finger joints 
in an individual can be determined by the evolution of' his finger joints through previously described anatomical phases: 
'N' (not affected), 'S' (classical OA), 'J' (loss of joint space), 'E' (erosive OA) and 'R' (remodeled joint). 
Structure/disease-modifying anti-OA drug (S/DMOAD) properties were searched for by assaying the number of 
patients developing OA in previously normal IP joints ('N' > 'S'), or progressing through the described anatomical 
phases of the disease ('S' > 'J', 'S' > 'E', 'J' > 'E', 'S' > 'R', 'J' > 'R', 'E' > 'R'). In the CS 4&6 group we observed a
significant decrease in the number of patients with new 'erosive' OA finger joints. This result is particularly important 
since OA of the finger joints becomes a clinical problem (pain, functional loss) when 'S' joints progress to 'J' and 
especially 'E' phases. During and after these 'E' phases, joints will remodel and show the nodular deformities 
characteristic of Heberden's and Bouchard's nodes. 
Treated patients were protected against erosive evolution. 
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THIS randomized, double-blind, placebo-control led 
study, including 119 patients, was designed to 
assess the S/DMOAD properties in osteoarthr it is  
(OA) of chondroit in sulfate (CS 4&6, Condrosulf" 
IBSA, Lugano, CH). Thirty-four of the patients 
received chondroit in sulfate 4&6 orally adminis- 
tered: 400 mg, three times daily. Placebo medi- 
cation was administered to 85 patients in total: 46 
of them belonged to a previous clinical trial and 39 
to the present study. All 119 patients were followed 
during 3 years. 
Posteranter ior  oentgenographies of the DIP 
and PIP joints and of the MCP joints of the 2nd, 
3rd, 4th and 5th fingers were obtained at the start  
of this prospective study and at yearly intervals. 
This enabled the investigators to document he 
radiological progression of the anatomical  lesions 
in the pathological finger joints over a 3-year 
period. 
It was shown that the progression of OA in the 
finger joints in an individual can be assessed by 
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the evolution of his/her finger joints through 
previously described anatomical  phases: 'N' (not 
affected), 'S' (classical OA), 'J ' (loss of joint space), 
'E' (erosive OA) and 'R' (remodeled joint) [1]. 
A structure/disease-modifying anti-OA drug 
(S/DMOAD) should decrease: (1) the number of 
patients developing OA in previously normal 
finger joints; (2) the number of patients developing 
'erosive' OA in osteo-arthrit ic finger joints. This 
last definition is part icular ly important since 
60 80% of individuals over 70 years of age have 
so-called 'S' OA and have been asymptomatic 
throughout  heir  lives. OA of the fingers joints 
becomes a clinical problem (pain, functional oss) 
when 'S' joints progress to 'J' and especially 'E' 
phases. During and after these 'E' phases, joints 
will remodel and show the nodular  deformities 
character ist ic of Heberden's and Bouchard's 
nodes. 
Structure and disease modifying anti-OA drug 
(S/DMOAD) propert ies were searched for by 
assaying the numbers of patients developing OA in 
previously normal finger joints (N > S), or pro- 
gressing through the described anatomical  phases 
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of the disease (S>J ,  S>E,  J>E ,  S>R,  J>R,  
E > R, S > N). The numbers of patients in the 
different treatment groups showing particular 
changes in their anatomical phases were compared 
using the chi-square test. 
It is obvious that similar pathogenetic mechan- 
isms lie behind the aggressive progression of 
osteoarthritis of the DIP and PIP joints. Therefore, 
DIP and PIP joints were considered as one single 
group of finger joints when the progression 
through the anatomical phases in the individual 
patients was studied. The evolution in the 
interphalageal (IP) joints during 3 years of 
follow-up is discussed. 
MCP joints, which were separately evaluated, 
were not influenced by CS 4&6. 
An analysis of the changes in the anatomical 
phases in each individual showed that compar- 
able numbers of patients in both treated and 
placebo groups developed OA in non-affected 
joints. However, in the CS 4&6-treated group, 
we observed a significant decrease in the 
number of patients with new 'erosive' OA finger 
joints. 
Some 8.8% of the patients had 'S' or 'J' joints 
becoming 'erosive' (2.9% of the patients had 'S' 
joints becoming 'erosive'; 5.9% of the patients had 
'J' joints becoming 'erosive'). In the untreated 
group 29.4% of the patients had 'S' or 'J' joints 
becoming 'erosive' (20.0% of the patients had 'S' 
joints becoming 'erosive'; 22.4% of the patients had 
'J' joints becoming 'erosive'). 
The pharmacologic mechanisms behind this 
effect can be a matter of discussion. Progression to 
the 'E' phase is characterized by erosive changes in 
the subchondral bone of these finger joints. Direct 
or indirect pharmacologic effects on the physi- 
ology of this tissue could have led to protection of 
the joint (the so-called S/DMOAD effect). 
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